Zhengtian Lv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhengtian Lv has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chenchen Meng
Zhejiang Chinese Medical University
2 shared publications - Tiantian Zheng
The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China
2 shared publications - Wei Mao
Department of Cardiology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications - Xinbin Zhou
Department of Cardiology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
2 shared publications Chenxia Wu
The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China; Department of Cardiology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication- Chenxia Wu
The First School of Clinical Medicine, Zhejiang Chinese Medical University, 310053 Hangzhou, Zhejiang, China
1 shared publication
Latest Publications
- Open Access
- 5 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 146, 157122
The Tanyu Tongzhi Formula enhances IL-10 expression and macrophage efferocytosis to alleviate atherosclerosis in mice
- 5 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 146, 157122
Open AccessThe Tanyu Tongzhi Formula enhances IL-10 expression and macrophage efferocytosis to alleviate atherosclerosis in mice
- Open Access
- 20 March 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (3) , 26740
The Critical Role of Faecalibacterium prausnitzii in Cardiovascular Diseases
Due to the continued aging of the global population, cardiovascular diseases (CVDs) remain the main cause of death worldwide, with millions of fatalities from diseases, including stroke and coronary artery disease, reported annually. Thus, novel therapeutic approaches and targets are urgently required for diagnosing and treating CVDs. Recent studies emphasize the vital part of gut microbiota in both CVD prevention and management. Among these, Faecalibacterium prausnitzii (F. prausnitzii) has emerged as a promising probiotic capable of improving intestinal health. Although preliminary investigations demonstrate that F. prausnitzii positively enhances cardiovascular health, research specifically connecting this strain to CVD outcomes remains limited. Based on current research and assessment of possible clinical applications, this paper aimed to investigate the positive effects on cardiovascular health using F. prausnitzii and its metabolites. Targeting gut flora is expected to become a mainstay in CVD treatment as research develops.
- 20 March 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (3) , 26740
Open AccessThe Critical Role of Faecalibacterium prausnitzii in Cardiovascular Diseases
Due to the continued aging of the global population, cardiovascular diseases (CVDs) remain the main cause of death worldwide, with millions of fatalities from diseases, including stroke and coronary artery disease, reported annually. Thus, novel therapeutic approaches and targets are urgently required for diagnosing and treating CVDs. Recent studies emphasize the vital part of gut microbiota in both CVD prevention and management. Among these, Faecalibacterium prausnitzii (F. prausnitzii) has emerged as a promising probiotic capable of improving intestinal health. Although preliminary investigations demonstrate that F. prausnitzii positively enhances cardiovascular health, research specifically connecting this strain to CVD outcomes remains limited. Based on current research and assessment of possible clinical applications, this paper aimed to investigate the positive effects on cardiovascular health using F. prausnitzii and its metabolites. Targeting gut flora is expected to become a mainstay in CVD treatment as research develops.